Integrating Biological Age Testing Into a Functional Medicine Practice: A Clinical Playbook

Functional medicine practices that already run comprehensive blood panels can add glycan-based biological age testing as a distinct inflammation layer without duplicating existing diagnostics. This approach measures IgG glycosylation, the sugar structures attached to immune antibodies that regulate chronic inflammation, giving practitioners a stable, repeatable marker of immune aging that responds to intervention within months rather than years. This playbook walks through how to baseline patients, structure retesting, and use results to guide protocols, positioned alongside the broader biological age testing category this method is built on.

Want the full picture? Read GlycanAge for Healthcare Providers, Functional Medicine Clinics & Corporate Wellness Programs.

What exactly does a GlycanAge test add to a functional medicine workup?

GlycanAge measures active, current chronic inflammation through IgG glycosylation, the pattern of complex sugars attached to immune antibodies that regulate how aggressively the immune system behaves. Standard functional medicine panels capture metabolic, hormonal, and lipid markers that fluctuate hour to hour, but they were never built to isolate the slow, low-grade inflammatory process known as inflammaging that drives age-related disease.

Results are grouped into five glycan indexes across two tiers. Three primary indexes, Glycan Shield and Glycan Youth (anti-inflammatory) and Glycan Mature (pro-inflammatory), are used to calculate the biological age itself. Two supportive indexes, Glycan Median and Glycan Bisection, don't factor into the age calculation but help narrow down associations with specific disease types, genetic traits, and lifestyle habits.

"Studying proteins without glycans is like studying birds without their feathers. You can understand their anatomy, but you cannot fully understand their function."

— Prof. Gordan Lauc, Professor of Biochemistry and Molecular Biology, University of Zagreb, and Co-Founder & Chief Scientific Officer, GlycanAge

This is why glycans matter as a distinct layer on top of standard panels: they're not a side detail on the antibody, they're what determines whether it behaves in a pro- or anti-inflammatory way. A report showing strong index scores gives the clinician an immediate, structured starting point for the consultation: common explanations include effective medications or therapies (particularly HRT), optimal lifestyle habits, or favorable genetic factors. Practices already running comprehensive blood chemistry can use GlycanAge as the missing inflammatory layer rather than a replacement for existing workups.

How is GlycanAge different from the epigenetic clocks and DNA tests already used in longevity medicine?

GlycanAge measures present-tense immune inflammation, while epigenetic clocks reflect historical gene expression patterns and DNA tests reveal fixed genetic potential that does not change with lifestyle. Published population-level data on epigenetic clocks shows a median prediction error in the range of 2.3 to 3.6 years, even in large, well-characterized cohorts, while GlycanAge shows a technical reproducibility of roughly plus or minus one year in repeat measurements taken close together. That reproducibility matters clinically: it means a change in a patient's GlycanAge result is more likely to reflect a real biological shift than measurement noise. For a functional medicine practice, this distinction determines what each tool is fit for: DNA and epigenetic tests for a one-time or slow-changing baseline, and GlycanAge for tracking whether this quarter's protocol is actually working.

Where should biological age testing sit in the patient intake and baselining process?

Order a GlycanAge test at intake, before any new protocol begins, so the result functions as a true pre-intervention baseline. Practitioners are encouraged to gather medication history, current therapies, and lifestyle habits alongside the result, because glycans can reflect effective hormone replacement therapy, other targeted pharmacological interventions, or undiagnosed inflammatory conditions the patient has not volunteered.

Clients frequently do not report supplements or off-label longevity therapies because they do not consider them "medication," making the intake conversation essential to interpreting the result correctly. Structure the client conversation around the executive summary and the biological age headline first, since most clients are testing specifically to see that number, then move into the underlying indexes to map likely drivers. This sequencing turns a report into a working clinical tool rather than a data dump.

How do I interpret a result that doesn't match the patient's presentation?

An unexpected result, biological age much lower or higher than chronological age, should prompt a structured follow-up rather than dismissal. Case documentation from GlycanAge partner clinics shows this pattern repeatedly: results that don't initially make sense are often explained once medication history, supplements, or recent life events come into the conversation. One documented case tracked a female client with Hashimoto's thyroiditis over five years, showing a sharp rise in biological age following pregnancy, followed by normalization as she recovered and adopted targeted lifestyle changes, with later fluctuations tracking adherence to those habits.

When a result surprises you, ask patients about medications, supplements, recent illness, and life events before assuming the number is wrong.

What should I do when a patient's result comes back worse than expected?

A high biological age result relative to chronological age should trigger a structured review of core lab investigations rather than an immediate change in protocol. Practices are advised to have a defined follow-up pathway for clients whose GlycanAge or index results are not where the practitioner hopes, particularly for those with genetic or family history predisposing them to cardiovascular disease or metabolic syndrome and diabetes.

Chronic, low-grade inflammation is the through-line connecting these risk categories, and glycan patterns give the practitioner a way to flag it before symptoms or standard blood markers shift. Build a short list of follow-up labs specific to your patient population's risk profile, and use the GlycanAge result as the trigger point for ordering them, not as a standalone verdict.

How often should patients retest, and what counts as a meaningful change?

Retest cadence depends on what's being tracked. For pharmaceutical or HRT-based interventions, retest at 3 to 4 months, since hormonal and pharmacological effects on glycans tend to show up in that window. For lifestyle-based interventions, such as diet, exercise, sleep, and stress management, retest at 6 to 12 months, since these changes accumulate more gradually. Both windows are fast enough to keep patients engaged in their protocol and slow enough to filter out day-to-day fluctuation, unlike blood panels that shift hourly or epigenetic clocks that move too slowly to give actionable feedback within a treatment cycle.

"I'd like to monitor my patients before they start HRT. We want to know how quickly we can reverse this pro-inflammation. It's really crucial to our future health."

— Dr. Louise Newson, Menopause Specialist, Founder of Newson Health

Repeated GlycanAge testing across years, as documented in the thyroiditis case above, shows the trajectory clearly: a rise during a health disruption, followed by normalization as the patient responds to treatment and lifestyle change, with the biological age line tracking against the chronological age line over time. Set the retest date at the same time you set the protocol, so both patient and practitioner have a fixed point to evaluate response.

Can GlycanAge validate hormone therapy, including HRT and thyroid replacement, in my patients?

Yes, GlycanAge is used in clinical practice to check whether hormone therapy is achieving genuine immune and metabolic benefit, not just symptom control. In one documented Raffaele Medical case, a 55-year-old woman four years past menopause was already on oral estrogen-progesterone therapy but still had an elevated GlycanAge relative to her chronological age, despite a disciplined lifestyle. After switching to a bioidentical estradiol cream with gradual dose adjustments, her GlycanAge decreased by 10 years over the following year.

For thyroid hormone therapy, data drawn from more than 9,000 participants in the Rotterdam Study showed that higher free thyroxine and lower thyroid-stimulating hormone levels, even within the normal reference range, were associated with increased cardiovascular risk, while appropriately titrated thyroxine replacement that restores true euthyroid status has been associated with reductions in biological age and improved glycan markers.

Clinicians should be cautious about over-replacement: excessive dosing that suppresses TSH or pushes FT4 toward the upper reference range may reduce these benefits and increase cardiovascular strain, so GlycanAge improvements should always be read alongside thyroid levels, cardiovascular status, and symptoms, not in isolation.

Is GlycanAge a diagnostic test I can use to identify disease?

No. GlycanAge is a biomarker for tracking immune aging and chronic inflammation, designed to be interpreted alongside clinical history and other lab data, not a standalone diagnostic. Its clinical value lies in flagging where inflammatory biology may be diverging from what a patient's chronological age or symptom picture would suggest, prompting further investigation rather than delivering a standalone verdict. Use it to open a clinical conversation: ask about medications, supplements, therapies, and family history when a result is unexpected, and follow up with core lab investigations for patients whose risk profile warrants it.

How do I introduce this to patients without overselling it?

Present GlycanAge as a way to see whether what you are already doing, whether medication, supplementation, or lifestyle change, is showing up in the body's inflammatory biology. Lead with the biological age number, since that is what most clients are testing to see, then walk through the indexes to explain the pattern behind it. Frame retesting as the natural next step in an ongoing protocol rather than a one-off curiosity purchase; this is what turns a single test into a recurring part of patient care.

Practices ready to build biological age testing into their patient workflow can review the clinical documentation and onboarding process on the Healthcare Providers page.

Book a partnership call to discuss integrating GlycanAge into your intake and retest protocols.

External sources

• https://pmc.ncbi.nlm.nih.gov/articles/PMC9976489/ — Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14:R115.

• https://pubmed.ncbi.nlm.nih.gov/29089349/ — Bano A, Chaker L, Mattace-Raso FUS, van der Lugt A, Ikram MA, Franco OH, Peeters RP, Kavousi M. Thyroid function and the risk of atherosclerotic cardiovascular morbidity and mortality: the Rotterdam Study. Circ Res. 2017 Dec 8;121(12):1392-1400.